pharma · Advanced Solid Tumors · Advanced Solid Tumor · MDNAF
Medicenna Therapeutics
Medicenna Therapeutics is a pharma organization headquartered in Toronto, CA. It trades on NYSE under ticker MDNAF. Primary therapeutic focus areas include Advanced Solid Tumors, Advanced Solid Tumor, Glioblastoma. NovaP
Toronto, CA HQ
24 Employees
Public company Type
MDNAF · NYSE Ticker
Company details
- Status
- Public
- HQ
- Toronto, CA
- Employees
- 24
- Programs
- 3
- Drugs
- 3
- Patents
- 9
MDNA11
Phase 2 · small molecule · Advanced Solid Tumor
MDNA11 for Advanced Solid Tumor is a Phase 2 program (small_molecule) at Medicenna Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MDNA11-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Medicenna Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced Solid Tumor
- Status
- active
- Trials
- 1